Fibroblast growth factor receptor 2 (FGFR2) is a transmembrane receptor tyrosine kinase that signals cell division, growth and differentiation. Defects in FGFR2 expression and signaling are oncogenic and occur in some of the most aggressive and common cancer types, including breast, prostate, esophageal and colorectal cancer. FGFR2 is therefore a promising early cancer biomarker and an important target for cancer therapy.
A small peptide that rapidly targets and binds to FGFR2 positive cancer cells
This technology is a 12amino acid peptide sequence identified by phage display that shows robust binding affinity and specificity for the extracellular domain of FGFR2. The binding properties of this peptide to FGFR2 and FGFR2 expressing tumor cells have been characteristics via multiple in vitro assays and validated with both pre-malignant and malignant biopsy specimens of human esophagus and stomach. Additionally, this peptide binds to the extracellular domain of FGFR2 without interfering with receptor signaling making it advantageous for diagnostic imaging. The fast target binding, low cost of production and reduced toxicity makes this peptide preferable to conventional monoclonal antibodies. This peptide is therefore a promising clinical tool for both the detection and targeted therapy of cancers linked to FGFR2 dysregulation.
- A diagnostic or therapeutic agent for early cancer detection, cancer staging, monitoring therapeutic response, guiding choice of therapy and targeted drug delivery.
- Reduced toxicity and low immunogenicity
- Enhanced tumor penetration
- Enhanced extravasation from leaky tumor vasculature
- Enhanced tissue diffusion
- Ability to achieve high drug concentration in tumors
- Fast target binding
- Reduced cost of production using Good Manufacturing Practices (GMP)
- Can be labeled with a wide range of reporters
- Compatible with diagnostic imaging approaches